Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy
Table 1
Characteristics of all patients with proliferative diabetic retinopathy enrolled in the study according to follow-up status.
Followed up
LTFU
All subjects
value
Number of eyes (%)
391 (83.7%)
76 (16.3%)
467
—
Baseline LogMAR BCVA (Snellen equivalent)
0.22 ± 0.07 (20/33)
0.26 ± 0.10 (20/36)
0.23 ± .08 (20/34)
0.001
Age (yrs)
57.11 ± 9.83
52.78 ± 8.25
56.40 ± 9.72
0.001
Gender, n (%)
0.93
Male
208 (83.9%)
40 (16.1%)
248
Female
183 (83.6%)
36 (16.4%)
219
Age category (yrs), n (%)
0.005
≤50 years
89 (76.1%)
28 (23.9%)
117
51–60 years
166 (83.0%)
34 (17.0%)
200
≥61 years
136 (90.7%)
14 (9.3%)
150
Procedure, n (%)
0.003
IVI
82 (91.1%)
8 (8.9%)
90
PRP
157 (87.2%)
23 (12.8%)
180
IVI + PRP
152 (77.2%)
45 (22.8%)
197
LogMAR BCVA at final follow-up (Snellen equivalent)
0.31 ± 0.28 (20/40)
0.47 ± 0.42 (20/59)
0.43 ± 0.32(20/43)
0.001
Data presented mean ± standard deviation and n (%) as applicable. For LTFU group, interventions represented were done before point of LTFU. BCVA = best corrected visual acuity, IVI = intravitreal injection, LogMAR = logarithm of the minimum angle resolution, LTFU = loss to follow-up, and PRP = panretinal photocoagulation.
